| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jan Jessen Krut, Henrik Zetterberg, Kaj Blennow, Paola Cinque, Lars Hagberg, Richard W Price, Marie Studahl, Magnus Gisslé. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of neurology. vol 260. issue 2. 2013-09-04. PMID:23052602. |
the cerebrospinal fluid (csf) biomarker profile in alzheimer's disease (ad) is characterized by decreased beta amyloid (aβ(1-42)), increased total and hyperphosphorylated tau (t-tau and p-tau, respectively), which is a useful diagnostic tool and gives insight in the pathogenesis of ad. |
2013-09-04 |
2023-08-12 |
Not clear |
| Gayathri Ramachandran, Jayant B Udgaonka. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies. Biochemistry. vol 52. issue 24. 2013-09-03. PMID:23721410. |
mechanistic studies unravel the complexity inherent in tau aggregation leading to alzheimer's disease and the tauopathies. |
2013-09-03 |
2023-08-12 |
Not clear |
| Gayathri Ramachandran, Jayant B Udgaonka. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies. Biochemistry. vol 52. issue 24. 2013-09-03. PMID:23721410. |
the aggregation of the protein tau into amyloid fibrils is known to be involved in the causation of the neurodegenerative tauopathies and the progression of cognitive decline in alzheimer's disease. |
2013-09-03 |
2023-08-12 |
Not clear |
| M Jeffre. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease. Neuropathology and applied neurobiology. vol 39. issue 3. 2013-08-28. PMID:23171056. |
in alzheimer's disease the membrane-spanning alzheimer's precursor protein (app) is progressively cleaved within the plasmalemma to form aβ peptide fragments that can form pathogenic extracellular aggregates while microtubule-associated tau proteins may also aggregate within neurones. |
2013-08-28 |
2023-08-12 |
Not clear |
| Ann Van der Jeugd, David Blum, Sylvie Raison, Sabiha Eddarkaoui, Luc Buée, Rudi D'Hoog. Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. Behavioural brain research. vol 242. 2013-08-27. PMID:23247080. |
thy-tau22 mice constitute an animal model for tau aggregation, a hallmark in alzheimer's disease (ad) and tauopathies. |
2013-08-27 |
2023-08-12 |
mouse |
| Edoardo Parrella, Tom Maxim, Francesca Maialetti, Lu Zhang, Junxiang Wan, Min Wei, Pinchas Cohen, Luigi Fontana, Valter D Long. Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model. Aging cell. vol 12. issue 2. 2013-08-27. PMID:23362919. |
protein restriction cycles reduce igf-1 and phosphorylated tau, and improve behavioral performance in an alzheimer's disease mouse model. |
2013-08-27 |
2023-08-12 |
mouse |
| Adam L Boxer, Michael Gold, Edward Huey, Fen-Biao Gao, Edward A Burton, Tiffany Chow, Aimee Kao, Blair R Leavitt, Bruce Lamb, Megan Grether, David Knopman, Nigel J Cairns, Ian R Mackenzie, Laura Mitic, Erik D Roberson, Daniel Van Kammen, Marc Cantillon, Kathleen Zahs, Stephen Salloway, John Morris, Gary Tong, Howard Feldman, Howard Fillit, Susan Dickinson, Zaven Khachaturian, Margaret Sutherland, Robert Farese, Bruce L Miller, Jeffrey Cumming. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 2. 2013-08-26. PMID:23043900. |
the close association of some forms of ftd with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating ftd may predict efficacy in more common diseases such as alzheimer's disease. |
2013-08-26 |
2023-08-12 |
Not clear |
| Melvyn J Ball, Walter J Lukiw, Eli M Kammerman, James M Hil. Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 2. 2013-08-26. PMID:23159044. |
a faulty human protein, abnormally phosphorylated tau, was recently publicized to spread "like a virus" from neuron to neuron in alzheimer's patients' brains. |
2013-08-26 |
2023-08-12 |
human |
| Ting Yang, Soyon Hong, Tiernan O'Malley, Reisa A Sperling, Dominic M Walsh, Dennis J Selko. New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 2. 2013-08-26. PMID:23375565. |
soluble oligomers of amyloid ß-protein (aß) have been increasingly linked to synaptic dysfunction, tau alteration, and neuritic dystrophy in alzheimer's disease (ad) and mouse models. |
2013-08-26 |
2023-08-12 |
mouse |
| Gianmario Ciaccioli, Ana Martins, Cátia Rodrigues, Helena Vieira, Patrícia Calad. A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. PloS one. vol 8. issue 2. 2013-08-26. PMID:23393603. |
several studies revealed consistent overlap between synucleinopathies and tauopathies, demonstrating that α-synuclein (asyn) and tau co-localize in neurofibrillary tangles and in lewy bodies from alzheimer's and parkinson's disease patients and corresponding animal models. |
2013-08-26 |
2023-08-12 |
human |
| D Ryan, D Koss, E Porcu, H Woodcock, L Robinson, B Platt, G Riede. Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent. Cellular and molecular life sciences : CMLS. vol 70. issue 14. 2013-08-26. PMID:23535719. |
we recently generated an advanced mouse model of alzheimer's disease (ad) by targeted knock-in of single-copy mutated human amyloid precursor-protein (app) and tau genes, crossed with a non-symptomatic presenilin (ps1a246e) over-expressing mouse line. |
2013-08-26 |
2023-08-12 |
mouse |
| Khalid Iqbal, Cheng-Xin Gong, Fei Li. Hyperphosphorylation-induced tau oligomers. Frontiers in neurology. vol 4. 2013-08-22. PMID:23966973. |
in alzheimer disease (ad) brain tau is three to fourfold hyperphosphorylated. |
2013-08-22 |
2023-08-12 |
Not clear |
| Eva Borger, Laura Aitken, Heng Du, Wenshen Zhang, Frank J Gunn-Moore, Shirley Shi Du Ya. Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease? Current Alzheimer research. vol 10. issue 1. 2013-08-21. PMID:22742981. |
current strategies for the treatment of alzheimer's disease (ad) involve tackling the formation or clearance of the amyloid-beta peptide (aβ) and/or hyper-phosphorylated tau, or the support and stabilization of the remaining neuronal networks. |
2013-08-21 |
2023-08-12 |
Not clear |
| Gustavo Basurto-Islas, Inge Grundke-Iqbal, Yunn Chyn Tung, Fei Liu, Khalid Iqba. Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. The Journal of biological chemistry. vol 288. issue 24. 2013-08-21. PMID:23640887. |
activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in alzheimer disease. |
2013-08-21 |
2023-08-12 |
Not clear |
| Gustavo Basurto-Islas, Inge Grundke-Iqbal, Yunn Chyn Tung, Fei Liu, Khalid Iqba. Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. The Journal of biological chemistry. vol 288. issue 24. 2013-08-21. PMID:23640887. |
neurofibrillary pathology of abnormally hyperphosphorylated tau is a key lesion of alzheimer disease and other tauopathies, and its density in the brain directly correlates with dementia. |
2013-08-21 |
2023-08-12 |
Not clear |
| Gustavo Basurto-Islas, Inge Grundke-Iqbal, Yunn Chyn Tung, Fei Liu, Khalid Iqba. Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. The Journal of biological chemistry. vol 288. issue 24. 2013-08-21. PMID:23640887. |
here we show that the level of activated asparaginyl endopeptidase is significantly increased, and this enzyme and i2(pp2a) translocate, respectively, from neuronal lysosomes and nucleus to the cytoplasm where they interact and are associated with hyperphosphorylated tau in alzheimer disease brain. |
2013-08-21 |
2023-08-12 |
Not clear |
| Catherine M Cowan, Amrit Mudhe. Are tau aggregates toxic or protective in tauopathies? Frontiers in neurology. vol 4. 2013-08-21. PMID:23964266. |
aggregation of highly phosphorylated tau into aggregated forms such as filaments and neurofibrillary tangles is one of the defining pathological hallmarks of alzheimer's disease and other tauopathies. |
2013-08-21 |
2023-08-12 |
human |
| Kerstin Morcinek, Christoph Köhler, Jürgen Götz, Hannsjörg Schröde. Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice. Brain research. vol 1497. 2013-08-20. PMID:23261664. |
to address the question whether tau filament forming mice expressing mutated human tau mirror histopathological changes observed in alzheimer brainstem, the degree and distribution of neurofibrillary lesions as well as the pattern of cholinergic and monoaminergic neurons were investigated. |
2013-08-20 |
2023-08-12 |
mouse |
| Kerstin Morcinek, Christoph Köhler, Jürgen Götz, Hannsjörg Schröde. Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice. Brain research. vol 1497. 2013-08-20. PMID:23261664. |
although numerous brainstem nuclei in our model expressed human tau protein, the development of neurofibrillary tangles, neuropil threads and ghost tangles was rare and likewise its distribution differed largely from alzheimer's disease pattern. |
2013-08-20 |
2023-08-12 |
mouse |
| Bruno Bulic, Marcus Pickhardt, Eckhard Mandelko. Progress and developments in tau aggregation inhibitors for Alzheimer disease. Journal of medicinal chemistry. vol 56. issue 11. 2013-08-20. PMID:23484434. |
progress and developments in tau aggregation inhibitors for alzheimer disease. |
2013-08-20 |
2023-08-12 |
Not clear |